Niagen Bioscience (NAGE) director receives 31,746-share stock option grant at $3.45

Rhea-AI Filing Summary

Niagen Bioscience director Hamed Shahbazi received a new stock option grant. The award covers 31,746 shares of Common Stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036, with no shares sold in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shahbazi Hamed

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	31,746	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 31,746 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 31,746 shares Exercise price: $3.45 per share Post-transaction derivative holdings: 31,746 options +2 more

5 metrics

Option grant size 31,746 shares Underlying Common Stock for new stock option

Exercise price $3.45 per share Stock option strike price

Post-transaction derivative holdings 31,746 options Total derivative securities following transaction

Vesting date June 24, 2027 Option vests 100% on this date

Expiration date June 23, 2036 Option expiration

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, vests 100%

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vests 100% financial

"Option vests 100% on June 24, 2027."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 05:57 PM Accepted by SEC EDGAR 06/26/2026 - 05:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shahbazi Hamed

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.45	06/24/2026		A		31,746		06/24/2027(1)	06/23/2036	Common Stock	31,746	$0	31,746	D

Explanation of Responses:

1. Option vests 100% on June 24, 2027.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Niagen Bioscience (NAGE) report for Hamed Shahbazi?

Niagen Bioscience reported a stock option grant to director Hamed Shahbazi for 31,746 shares of Common Stock. The option has an exercise price of $3.45 and represents a compensation-related award, not an open-market share purchase or sale.

How many Niagen Bioscience (NAGE) shares are covered by Shahbazi’s new option?

The new stock option granted to Hamed Shahbazi covers 31,746 underlying shares of Niagen Bioscience Common Stock. These shares become purchasable only if the option vests and is exercised according to its terms and dates described in the filing.

What is the exercise price of Hamed Shahbazi’s Niagen Bioscience option grant?

The option granted to Hamed Shahbazi has an exercise price of $3.45 per share. This means he can purchase up to 31,746 shares of Niagen Bioscience Common Stock at $3.45 if he exercises the option after it has vested.

When does Hamed Shahbazi’s Niagen Bioscience stock option vest and expire?

The option vests 100% on June 24, 2027, giving Shahbazi full exercisability on that date. It expires on June 23, 2036, so any unexercised portion after that date will lapse under the terms disclosed in the filing.

Did Hamed Shahbazi buy or sell Niagen Bioscience (NAGE) shares in this Form 4?

No open-market purchases or sales occurred in this Form 4. The filing reports a grant of a stock option, categorized as a grant, award, or other acquisition, rather than a typical market transaction involving existing Common Stock.

How many Niagen Bioscience derivative securities does Shahbazi hold after this grant?

Following this transaction, Shahbazi holds 31,746 stock options as reported in the filing. These options represent rights to acquire Common Stock, subject to the vesting date of June 24, 2027 and the expiration date of June 23, 2036.